(Booth 1316) Medical imaging software and services provider Cedara Software will display two products for the molecular imaging market.
The Mississauga, Ontario-based unit of Merge Healthcare offers Cedara I-Response, a clinical workstation specifically designed to track changes in tumors at the metabolic or cellular level. It is used to help evaluate, assess, and monitor the effect of cancer therapy over time by supporting longitudinal studies with PET/CT analysis, RECIST (response evaluation criteria in solid tumors) analysis, and morphology segmentation.
In addition to providing tools for standard anatomical measurements, I-Response is designed to analyze both PET/CT and MR-based diffusion-weighted imaging (DWI) protocols. I-Response also features patented functional diffusion map (fDM) technology to analyze DWI studies to visualize and quantify changes over time.
I-Response has been cleared by the U.S. Food and Drug Administration (FDA), and the company is marketing the software to OEM companies involved in oncology research, drug development, and oncology treatment, as well as imaging equipment manufacturers, PACS vendors, and researchers.
At RSNA 2007, Cedara also will demonstrate as a work-in-progress a new version of I-Response based on the company's C4 platform, an integration framework that enables modular integration of clinical applications.
In addition, the company will show its Cedara PET/CT software, which features PET/CT viewing streamlined to enhance radiologist workflow. The company has also designed a work-in-progress version of Cedara PET/CT, running as a C4 plug-in designed to help OEMs integrate Cedara PET/CT workflow into their products.
The Cedara PET/CT software is intended to enhance performance within a two-monitor environment. User-selected display layouts across two monitors are designed to facilitate workflow with layouts for simultaneous display of CT, PET-corrected, PET-uncorrected, and PET/CT fused images together with maximum intensity projection (MIP) displays. The software is FDA-cleared and currently available.
